Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2022 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
AMLX on Nasdaq
Shares outstanding
109,628,845
Price per share
$12.08
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
109,720,694
Total reported value
$1,491,122,082
% of total 13F portfolios
0.01%
Share change
+28,023,346
Value change
+$396,029,824
Number of holders
168
Price from insider filings
$12.08
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 11% $154,666,182 11,379,207 FMR LLC 30 Sep 2025
PERCEPTIVE ADVISORS LLC 8.2% -6.7% $121,662,640 +$14,650,251 8,952,365 +14% Perceptive Advisors LLC 30 Sep 2025
BlackRock, Inc. 7.1% +32% $94,028,025 +$34,623,629 7,783,648 +58% BlackRock, Inc. 31 Dec 2025
Adage Capital Management, L.P. 6.4% -35% $92,640,693 -$26,951,307 6,816,828 -23% Adage Capital Management, L.P. 30 Sep 2025
Commodore Capital LP 5.1% $89,213,500 5,650,000 Commodore Capital LP 10 Nov 2025
VANGUARD GROUP INC 4.9% -2% $71,672,372 +$10,542,372 5,273,750 +17% The Vanguard Group 30 Sep 2025
Point72 Asset Management, L.P. 2.6% -54% $38,074,233 -$26,039,432 2,801,636 -41% Point72 Asset Management, L.P. 30 Sep 2025
Panacea Innovation Ltd 2.6% $7,678,000 2,200,000 Panacea Venture Healthcare Fund II, L.P. 31 Dec 2024

As of 30 Sep 2025, 168 institutional investors reported holding 109,720,694 shares of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX). This represents 100% of the company’s total 109,628,845 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 10% 11,379,207 +273% 0.01% $154,643,424
PERCEPTIVE ADVISORS LLC 8.2% 8,952,365 +13% 3.6% $121,662,640
BlackRock, Inc. 6.5% 7,140,692 +30% 0% $97,042,005
ADAGE CAPITAL PARTNERS GP, L.L.C. 6.2% 6,816,828 -23% 0.15% $92,640,693
TCG Crossover Management, LLC 5.7% 6,243,812 +5% 4.2% $84,853,405
VANGUARD GROUP INC 4.8% 5,273,750 +17% 0% $71,670,263
Saturn V Capital Management LP 4.2% 4,604,878 +41% 14% $62,580,292
Commodore Capital LP 3.7% 4,075,478 2.7% $55,385,746
First Light Asset Management, LLC 3.1% 3,355,882 4.3% $45,606,436
Point72 Asset Management, L.P. 2.5% 2,790,066 -38% 0.08% $37,916,998
JANUS HENDERSON GROUP PLC 2.3% 2,536,233 0.02% $34,454,725
Driehaus Capital Management LLC 2.2% 2,420,767 +91% 0.24% $32,898,224
Almitas Capital LLC 1.9% 2,122,597 0% 6.6% $28,846,093
GOLDMAN SACHS GROUP INC 1.8% 2,010,633 +55% 0% $27,324,503
MORGAN STANLEY 1.8% 1,950,301 +301% 0% $26,504,591
Paradigm Biocapital Advisors LP 1.7% 1,900,000 0.76% $25,821,000
GEODE CAPITAL MANAGEMENT, LLC 1.7% 1,812,039 +7.1% 0% $24,631,001
683 Capital Management, LLC 1.6% 1,760,000 -19% 2.2% $23,918,400
GREAT POINT PARTNERS LLC 1.6% 1,700,000 -15% 9.6% $23,103,000
STATE STREET CORP 1.5% 1,621,260 +61% 0% $22,032,923
EVENTIDE ASSET MANAGEMENT, LLC 1.4% 1,512,500 0.34% $20,554,948
Balyasny Asset Management L.P. 1.3% 1,476,302 0.04% $20,062,944
Logos Global Management LP 1.3% 1,450,000 1.9% $19,705,500
UBS Group AG 1.3% 1,404,471 +12% 0% $19,086,761
DEUTSCHE BANK AG\ 1.2% 1,365,521 +121% 0.01% $18,557,430

Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 65,029 $785,731 -$524,304 $12.08 9
2025 Q3 109,720,694 $1,491,122,082 +$396,029,824 $13.59 168
2025 Q2 81,690,006 $523,632,250 +$57,316,518 $6.41 131
2025 Q1 73,877,500 $261,528,744 +$85,099,356 $3.54 134
2024 Q4 49,783,588 $188,178,786 +$19,456,848 $3.78 120
2024 Q3 43,406,257 $140,608,833 +$5,128,346 $3.24 109
2024 Q2 43,634,536 $82,910,614 -$16,890,632 $1.90 119
2024 Q1 49,483,582 $140,533,695 -$232,734,295 $2.84 145
2023 Q4 33,518 $493,385 -$16,708,819 $14.72 2
2023 Q3 58,927,724 $1,078,967,056 +$85,370,484 $18.31 168
2023 Q2 54,460,975 $1,174,838,680 +$53,634,951 $21.57 152
2023 Q1 51,372,917 $1,507,230,828 +$73,671,336 $29.34 145
2022 Q4 48,530,384 $1,793,199,591 +$430,308,805 $36.95 130
2022 Q3 36,575,728 $1,029,606,460 +$308,429,683 $28.15 88
2022 Q2 26,620,916 $512,892,346 +$61,856,096 $19.26 73
2022 Q1 23,330,516 $298,773,403 +$298,732,199 $12.85 70